| Document |
Document Title |
|
WO/2022/229441A2 |
The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to a composition comprising a specific combination of lipids and optionally one or more additives, and a method of preparing s...
|
|
WO/2022/232790A1 |
Provided are methods for treating an ocular disease in an individual, comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to an eye of the individual, wherein the rAAV particles comprise: a) a nucl...
|
|
WO/2022/232257A1 |
Provided herein are compositions and methods for delivering a molecular therapeutic to the cochlea of a subject. The methods comprise administering an adeno-associated virus (AAV) to the cerebrospinal fluid of the subject. The AAVs encod...
|
|
WO/2022/230977A1 |
The present invention provides: a graft material of retinal pigment epithelial cells, which can be prepared within a short period of time and at low cost and can be controlled easily at a site at which the graft material is transplanted ...
|
|
WO/2022/228546A1 |
The present application relates to a method and pharmaceutical composition for treating myopia. The pharmaceutical composition or the method of the present application can effectively prevent and control myopia, is safe and has no obviou...
|
|
WO/2022/232597A1 |
The invention provides methods, compositions, and kits containing a first therapeutic agent that is a substituted 2,3-dimethoxyquinone of Formula I, or a pharmaceutically acceptable salt thereof, for treating patients suffering from diab...
|
|
WO/2022/229787A1 |
The invention relates to a biocompatible product having a crosslinked matrix, in which a polysaccharide is co-crosslinked with chitosan, chitosan derivative, or chitosan salt, said matrix further comprising a divalent zinc cation.
|
|
WO/2022/232001A1 |
The present invention provides compositions, e.g., pharmaceutical compositions, which include a recombinant adeno-associated viral (AAV) expression construct, AAV vectors, AAV particles, and methods of treating a subject having a degener...
|
|
WO/2022/228413A1 |
Disclosed in the present invention are an RIPK1 inhibitor for inhibiting programmed cell death and a preparation method therefor. The RIPK1 inhibitor of the present invention is as represented by general formula I, wherein X, Y, Z, L, R1...
|
|
WO/2022/232249A1 |
The present disclosure relates to methods for regulating cholesterol efflux in retinal pigment epithelium cells and treating or preventing a neurodegenerative disease or disorder (e.g., macular degeneration).
|
|
WO/2022/225476A1 |
The present invention relates to injectable viscoelastic formulations which are developed by means of synergistic effect of hyaluronic acid (HA), vitamins, minerals, antioxidants and osmoprotectants, and which can be used in intraarticul...
|
|
WO/2022/225422A1 |
The present invention relates to a compound of formula (I): where Z is (II) in which R1 and R2 are identical or different and are hydrogen or a lower alkyl chain having up to 4 carbon atoms or a pharmaceutically acceptable salt thereof. ...
|
|
WO/2022/226347A1 |
Provided herein are pharmaceutical compositions and related methods for treating ophthalmic diseases. The method entails administering to the patient an effective amount of a CSF1R inhibitor, such as an anti-CSF1R antibody. The methods a...
|
|
WO/2022/222869A1 |
The present invention relates to a recombinant adeno-associated virus (AAV) and an application thereof. The present invention further relates to an AAV purification method and a purified AAV obtained thereby. The AAV in the present inven...
|
|
WO/2022/226187A1 |
This disclosure provides a method of stabilizing the interaction of a Retinoic Acid Receptor- alpha (RARα) and a corepressor, Nuclear Receptor Corepressor 1 (NCoRl) by contacting the RARa with an amount of a Chaperone Mediated Autophagy...
|
|
WO/2022/225182A1 |
The present invention relates to an anti-angiopoietin-2 (Ang2) antibody or an antigen-binding fragment thereof that specifically binds to Ang2 and induces Tie2 activation, comprising: (a) a heavy-chain complementarity-determining region ...
|
|
WO/2022/226286A1 |
The invention provides methods, compositions, and kits containing an alpha adrenergic antagonist such as phentolamine, either alone or in combination with a muscarinic acetylcholine receptor agonist such as pilocarpine, for treating cond...
|
|
WO/2022/222205A1 |
Provided in the present invention are an amoxicillin capsule and a preparation method therefor, belonging to the technical field of drug preparation. 10-35 wt% of light amoxicillin powder with a particle size of less than 0.180 mm and 10...
|
|
WO/2022/223140A1 |
The present invention relates to new engineered fusion proteins with for use in treating disorders of the eye. In particular, the new fusion proteins are capable of binding both VEGF- A and Type II collagen. The fusion proteins comprise ...
|
|
WO/2022/223661A1 |
Disclosed are TRPM8 modulators of formula (I) for achieving a cooling effect on skin and mucousa.
|
|
WO/2022/225359A1 |
The present invention relates to a composition for preventing or treating nonsyndromic deafness and a composition for diagnosing same. The present invention effectively controls the accumulation, in the cytoplasm, of mutated OSBPL2 prote...
|
|
WO/2022/223644A2 |
The present invention relates to the combination of a nucleic acid encoding a short isoform of rod-derived cone viability factor (RdCVF), a nucleic acid encoding a long isoform of rod-derived cone viability factor (RdCVFL) and a nucleic ...
|
|
WO/2022/221741A1 |
CRISPR/RNA-guided nuclease-related compositions and methods for treatment of RHO-associated retinitis pigmentosa, e.g., autosomal-dominant retinitis pigmentosa (adRP).
|
|
WO/2022/218446A1 |
Disclosed is a use of a novel light sensitive channel protein VR 1.0 in the preparation of a retinal photoreceptor cell degenerative disease drug, belonging to the field of biomedicine. The amino acid sequence of the present light sensit...
|
|
WO/2022/219050A1 |
Present invention relates to colloidal suspension of single crystal cerium oxide nanoparticles for use in the treatment of a disorder or disease of the posterior segment of the eye, said treatment comprising administration of a topical o...
|
|
WO/2022/217923A1 |
Provided in the present invention is an antibody that can bind to IGF-1R. The antibody is composed of a light chain and a heavy chain, and the light chain and the heavy chain are selected from one of the combinations of SEQ ID NO:70 and ...
|
|
WO/2022/221395A1 |
Provided herein are embodiments relating to treating various eye disorders, including, for example, wAMD, DME, RVO, and DR.
|
|
WO/2022/218429A1 |
The present application relates to a bicyclic substituted aromatic carboxylic acid compound, and in particular to a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof. In formula (I), R2 and R3 and atom...
|
|
WO/2022/218381A1 |
The present invention relates to the use of calycosin and/or calycosin-7-glucoside in the treatment of autoimmune diseases. The present invention relates to the use of a composition containing calycosin and/or calycosin-7-glucoside in th...
|
|
WO/2022/221071A1 |
A co-drug or a pharmaceutical salt thereof includes a muscarinic agonist moiety and an alpha2 adrenergic agonist moiety. The muscarinic agonist moiety and the alpha2 adrenergic agonist moiety are connected covalently via a linker, and th...
|
|
WO/2022/221351A1 |
The present invention relates to methods of treating neuropathic corneal pain (NCP) comprising administration of nerve growth factor (NGF).
|
|
WO/2022/217110A1 |
Provided herein are compositions and methods comprising non-naturally occurring nucleic acid sequences that encode biologics. Also provided are methods of utilizing the provided compositions and methods as ocular therapeutics for prevent...
|
|
WO/2022/216832A1 |
The present disclosure provides methods of treating subjects having an immune disorder by administering to the subject a therapeutically effective amount of an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor in combination with ...
|
|
WO/2022/216845A1 |
The disclosure provides compositions and methods for the treatment of hearing loss disorder.
|
|
WO/2022/217142A1 |
Among the various aspects of the present disclosure is the provision of compositions and methods of making regulatable, adeno-associated viral vectors for the therapeutic expression of CRX and methods of use thereof.
|
|
WO/2022/217194A1 |
A prefilled syringe containing a sterile ophthalmic pharmaceutical composition comprising an ultraconcentrated hydrogel and a pharmaceutically acceptable carrier, the prefilled syringe capable of storing the ultraconcentrated hydrogel an...
|
|
WO/2022/211547A1 |
The present invention relates to Paracoccus sp. bacterium-derived vesicles and a use thereof. The present inventors have experimentally confirmed that Paracoccus sp. bacterium-derived vesicles efficiently inhibit pathogenic biological fa...
|
|
WO/2022/211543A1 |
The present invention relates to a peptide binding to both a VEGF receptor and a PDGF receptor, a use thereof, and a selection method therefor.
|
|
WO/2022/208375A1 |
Compound with formula (1) for use in a method for treating a disease or disorder capable of being treated by an agonist of AdipoR. e.g. diabetic neuropathy.
|
|
WO/2022/207924A1 |
The present invention relates to compounds of formula (I). The compounds of the formula (I) are e.g. (S)-1-(5-((pyridin-3-yl)thio) pyrazin-2-yl)-4lH,6'H-spiro[piperidine-4,5'-pyrrolo[l,2-b]py
razol]-4l- amine derivatives and similar comp...
|
|
WO/2022/212360A1 |
The present disclosure relates generally to methods for treating choroidal neovascularization in a subject in need thereof using anti-ANG-2 × VEGF multi-specific antibodies.
|
|
WO/2022/208084A1 |
The invention provides methods for treating, preventing or reversing retinal degeneration. The methods administering to the subject a vector that expresses a Cadherin-related family member 1 (CDHR1) polypeptide. The invention also provid...
|
|
WO/2022/207773A1 |
A pharmaceutical formulation comprising laquinimod or a pharmaceutically acceptable salt thereof as active ingredient, a pharmaceutically acceptable viscosity agent, a pharmaceutically acceptable tonicity adjusting agent, a pharmaceutica...
|
|
WO/2022/206705A1 |
The present invention provides a heterocyclic compound as a TYK2 pseudokinase (JH2) domain inhibitor, a synthetic method, and use. In particular, the present invention provides a heterocyclic compound as represented by formula I, or a ph...
|
|
WO/2022/206339A1 |
The present invention relates to the field of biological medicine, and provides an application of OSI-906. OSI-906 is a small molecular compound, which may inhibit the signal transduction, proliferation and cytokine secretion of a tyrosi...
|
|
WO/2022/210784A1 |
Provided are suspension eye drops having superior re-dispersibility. The present disclosure provides an aqueous suspension agent that contains (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,
7,8-tetrahydronaphthalene-1-yl)...
|
|
WO/2022/204594A1 |
Provided is the intravitreal dosing of recombinant adeno-associated virus (rAAV)-based gene therapies for the treatment of color vision deficiencies such as Blue Cone Monochromacy (BCM) and Red-Green Color Blindness.
|
|
WO/2022/204111A1 |
Described are pharmaceutical compositions for treating an ophthalmic condition, the composition including i) a cannabinoid and ii) a modulator compound that acts as one or more of an NMD A receptor modulator, a 5-HT3 receptor modulator, ...
|
|
WO/2022/200224A1 |
The present invention provides a compound for use in the treatment of sinusitis, pneumonia or otitis in a subject, wherein said compound is a compound of Formula (I) as defined herein: AA-AA-AA-X-Y-Z (I). The invention further provides a...
|
|
WO/2022/204332A1 |
The present application provides anti-Met antibodies, or antigen-binding proteins, pharmaceutical compositions for wound healing or tissue regeneration that includes the anti- Met antibodies or antigen-binding proteins, as well as method...
|
